drugset / Trial / NCT04110418

Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate

NCT04110418

Phase 2 Unknown 36 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, prospective study comparing methylene blue versus terlipressin in treatment of catecholamines resistant shock in preterm neonate

Timeline

Start
2019-02-19
Primary completion
2020-02-19
Completion
2020-02-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylene Blue Diagnostic / imaging agent 0.15 mg/kg Intravenous
Comparator Terlipressin Peptide 20 ug/kg Intravenous

Indications